Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Schild

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 18, 2011
Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expressionFieke Lamers, Linda Schild, Jan Koster, et al.
BMC Cancer|July 14, 2012
Identification of BIRC6 as a novel intervention target for neuroblastoma therapyFieke Lamers, Linda Schild, Jan Koster, et al.
Endocrine-Related Cancer|August 24, 2011
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastropheFieke Lamers, Ida van der Ploeg, Linda Schild, et al.
European Journal of Cancer (Oxford, England : 1990)|February 28, 2012
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growthFieke Lamers, Linda Schild, Ilona J M den Hartog, et al.
Cancer Research|August 18, 2018
RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in NeuroblastomaThomas F Eleveld, Linda Schild, Jan Koster, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2020
Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responsesNil A Schubert, Linda Schild, Stijn van Oirschot, et al.
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumoursLaurel T Bate-Eya, Marli E Ebus, Jan Koster, et al.
Plos One|August 4, 2023
Two opposing gene expression patterns within ATRX aberrant neuroblastomaMichael R van Gerven, Linda Schild, Jennemiek van Arkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno-Smith, Anna Lakoma, Zaowen Chen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|November 18, 2011
Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expressionFieke Lamers, Linda Schild, Jan Koster, et al.
BMC Cancer|July 14, 2012
Identification of BIRC6 as a novel intervention target for neuroblastoma therapyFieke Lamers, Linda Schild, Jan Koster, et al.
Endocrine-Related Cancer|August 24, 2011
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastropheFieke Lamers, Ida van der Ploeg, Linda Schild, et al.
European Journal of Cancer (Oxford, England : 1990)|February 28, 2012
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growthFieke Lamers, Linda Schild, Ilona J M den Hartog, et al.
Cancer Research|August 18, 2018
RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in NeuroblastomaThomas F Eleveld, Linda Schild, Jan Koster, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2020
Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responsesNil A Schubert, Linda Schild, Stijn van Oirschot, et al.
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumoursLaurel T Bate-Eya, Marli E Ebus, Jan Koster, et al.
Plos One|August 4, 2023
Two opposing gene expression patterns within ATRX aberrant neuroblastomaMichael R van Gerven, Linda Schild, Jennemiek van Arkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno-Smith, Anna Lakoma, Zaowen Chen, et al.
Pageof 2